keyword
MENU ▼
Read by QxMD icon Read
search

Aloxi palonosetron

keyword
https://www.readbyqxmd.com/read/27571447/synthesis-and-pharmacological-evaluation-of-11-c-granisetron-and-18-f-fluoropalonosetron-as-pet-probes-for-5-ht3-receptor-imaging
#1
Linjing Mu, Adrienne Müller Herde, Pascal M Rüefli, Filippo Sladojevich, Selena Milicevic Sephton, Stefanie D Krämer, Andrew J Thompson, Roger Schibli, Simon M Ametamey, Martin Lochner
Serotonin-gated ionotropic 5-HT3 receptors are the major pharmacological targets for antiemetic compounds. Furthermore, they have become a focus for the treatment of irritable bowel syndrome (IBS) and there is some evidence that pharmacological modulation of 5-HT3 receptors might alleviate symptoms of other neurological disorders. Highly selective, high-affinity antagonists, such as granisetron (Kytril®) and palonosetron (Aloxi®), belong to a family of drugs (the 'setrons') that are well established for clinical use...
August 29, 2016: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/26913757/exposure-response-of-palonosetron-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-pediatric-patients
#2
Jian Wang, Nitin Mehrotra, Insook Kim, Sue-Chih Lee, Farrokh Sohrabi, Ruyi He, Andrew Mulberg, Vikram Sinha, Hae-Young Ahn, Dennis Bashaw, Donna Griebel
OBJECTIVES: Extrapolation of efficacy from adult populations to pediatrics may be appropriate if it is reasonable to assume that the 2 populations have similar disease progression and response to intervention. When full extrapolation of efficacy is deemed appropriate, the pediatric dose can be determined by "matching" exposure to a drug with that observed in adult patients. This approach has been used in certain therapeutic areas to alleviate the burden of pediatric clinical trials. We present here a case in which exposure matching is not appropriate...
October 2016: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/24128813/exploring-a-potential-palonosetron-allosteric-binding-site-in-the-5-ht-3-receptor
#3
Marta Del Cadia, Francesca De Rienzo, David A Weston, Andrew J Thompson, Maria Cristina Menziani, Sarah C R Lummis
Palonosetron (Aloxi) is a potent second generation 5-HT(3) receptor antagonist whose mechanism of action is not yet fully understood. Palonosetron acts at the 5-HT(3) receptor binding site but recent computational studies indicated other possible sites of action in the extracellular domain. To test this hypothesis we mutated a series of residues in the 5-HT3A receptor subunit (Tyr(73), Phe(130), Ser(163), and Asp(165)) and in the 5-HT3B receptor subunit (His(73), Phe(130), Glu(170), and Tyr(143)) that were previously predicted by in silico docking studies to interact with palonosetron...
December 1, 2013: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/23984894/palonosetron-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting
#4
REVIEW
Sherry Mori-Vogt, Marlo Blazer
Chemotherapy-induced nausea and vomiting (CINV) remains both a feared side effect of cancer treatment and a focus of many supportive care initiatives/guidelines. The class of medications known as serotonin receptor antagonists (5-HT3RAs) are integral in the prevention of CINV from both moderately and highly emetogenic chemotherapy. Palonosetron (ALOXI(®)), a second-generation 5-HT3RA, has a higher affinity for the 5-HT3 receptor, has a longer half-life and has unique interactions with the 5-HT3 receptor compared with the current first-generation 5-HT3RA such as ondansetron, granisetron, dolasetron and tropisetron...
August 2013: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/23924770/compatibility-and-stability-of-aloxi-palonosetron-hydrochloride-admixed-with-dexamethasone-sodium-phosphate
#5
Lawrence A Trissel, Yanping Zhang
The purpose of this study was to evaluate the physical and chemical stability of palonosetron hydrochloride 0.25 mg admixed with dexamethasone (as sodium phophate) 10 mg or 20 mg in 5% dextrose injection or 0.9% sodium chloride injection in polyvinylchloride minibags, and also admixed with dexamethasone (as sodium phosphate) 3.3 mg in 5% dextrose injection or 0.9% sodium chloride injection in polypropylene syringes, at 4 deg C stored in the dark for 14 days, and at 23 deg C exposed to normal laboratory fluorescent light over 48 hours...
September 2004: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/23354552/efficacy-of-oral-palonosetron-compared-to-intravenous-palonosetron-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-associated-with-moderately-emetogenic-chemotherapy-a-phase-3-trial
#6
RANDOMIZED CONTROLLED TRIAL
Ralph Boccia, Steven Grunberg, Edwin Franco-Gonzales, Edward Rubenstein, Daniel Voisin
BACKGROUND: Palonosetron (Aloxi(®), Onicit(®)) is a pharmacologically unique 5-HT3 receptor antagonist (RA) approved as a single IV injection for the prevention of nausea and vomiting induced by chemotherapy (CINV) of either moderate or highly emetogenic potential (MEC and HEC, respectively). An oral palonosetron formulation has been developed and compared to the IV formulation. METHODS: In this multinational, multicenter, double-blind, double-dummy, dose-ranging trial, 651 patients were randomly assigned to receive one of the following as a single dose prior to moderately emetogenic chemotherapy: oral palonosetron 0...
May 2013: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/20702972/-pharmacological-pharmacokinetic-and-clinical-profile-of-palonosetron-hydrochloride-aloxi-i-v-injection-0-75-mg-a-novel-antiemetic-5-ht3-receptor-antagonist
#7
REVIEW
Hirofusa Ajioka, Fumio Morita, Yushiro Akizawa, Kenichiro Yoshida, Ryuichi Kitamura, Hisami Takimoto
No abstract text is available yet for this article.
August 2010: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
https://www.readbyqxmd.com/read/18839220/palonosetron-aloxi-and-dexamethasone-for-the-prevention-of-acute-and-delayed-nausea-and-vomiting-in-patients-receiving-multiple-day-chemotherapy
#8
Maurizio Musso, Renato Scalone, Vincenza Bonanno, Alessandra Crescimanno, Vita Polizzi, Ferdinando Porretto, Carlo Bianchini, Tania Perrone
OBJECTIVE: The objective of this study was to determine the efficacy of palonosetron combined with dexamethasone in prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving multiple-day chemotherapy and the efficacy of a second dose of palonosetron in treating breakthrough emesis. MATERIALS AND METHODS: Forty-six patients treated with multiple-day chemotherapy for hematologic malignancies received palonosetron as prophylaxis for CINV on the first day of chemotherapy and dexamethasone throughout the entire period of chemotherapy...
February 2009: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/18516316/palonosetron-as-an-anti-emetic-and-anti-nausea-agent-in-oncology
#9
Matti S Aapro
Palonosetron (Aloxi(®), Onicit(®), Paloxi(®)) is a second-generation 5-HT(3) receptor antagonist (RA) with an extended half-life of ~40 hours and high binding affinity for the 5-HT₃ receptor that is markedly different from other 5-HT(3) RAs. Phase III trials demonstrate that a single dose of palonosetron compared with traditional 5-HT₃ RAs is more effective in preventing chemotherapy-induced nausea and vomiting (CINV) during the first 24 hours following chemotherapy (acute CINV), and also exhibits prolonged efficacy to provide significantly better protection from CINV in the delayed and overall phases...
December 2007: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/17715696/chemotherapy-induced-nausea-and-vomiting-which-antiemetic-for-which-therapy
#10
REVIEW
Lee S Schwartzberg
Chemotherapy-induced nausea and vomiting (CINV) remains an important and common toxicity of cancer treatment. Recent guideline revisions have classified chemotherapeutic agents into four categories of emesis risk without the use of preventive agents: high (> 90%), moderate (30%--90%), low (10%-30%), and minimal (< 10%). Currently available antiemetic agents, including corticosteroids, 5-hydroxytryptamine (HT)3 receptor antagonists, and neurokinin (NK)-1 antagonists are used alone or in combination depending on the level of emetogenic potential as prophylaxis against the development of CINVduring the acute period (up to 24 hours after chemotherapy) and the delayed period (up to 5 days after treatment)...
July 2007: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/17106506/palonosetron-aloxi-a-second-generation-5-ht%C3%A2-receptor-antagonist-for-chemotherapy-induced-nausea-and-vomiting
#11
Andrew De Leon
In July 2003, the Food and Drug Administration approved palonosetron hydrochloride injection for the treatment of chemotherapy-induced nausea and vomiting (CINV). The newest agent in the class of 5-HT₃ receptor antagonists (5-HT₃RAs), palonosetron differs from other agents in its class by its higher receptor-binding affinity and longer half-life. These pharmacological properties have resulted in improved antiemetic activity in clinical trials, particularly in the treatment of delayed CINV following moderate emetogenic chemotherapy...
October 2006: Proceedings of the Baylor University Medical Center
https://www.readbyqxmd.com/read/17034670/new-approaches-to-chemotherapy-induced-nausea-and-vomiting-from-neuropharmacology-to-clinical-investigations
#12
REVIEW
Edward B Rubenstein, Barbara S Slusher, Camilo Rojas, Rudolph M Navari
Nausea and vomiting are considered to be among the most distressing consequences of cytotoxic chemotherapies. Currently, there are several novel 5-HT(3) receptor antagonists for the treatment of chemotherapy-induced nausea and vomiting (CINV), including ondansetron, granisetron, and dolasetron. These agents provide significant improvement in the management of acute emesis but are ineffective at preventing delayed emesis. In 2003, a new 5-HT(3) receptor antagonist, palonosetron HCL (Aloxi), was introduced to the U...
September 2006: Cancer Journal
https://www.readbyqxmd.com/read/15561811/granisetron-an-update-on-its-clinical-use-in-the-management-of-nausea-and-vomiting
#13
REVIEW
Matti Aapro
Nausea and vomiting are typical side effects of cytotoxic therapy and some surgical procedures. These symptoms can represent a major therapeutic challenge and, if inadequately controlled by antiemetic treatment, will result in increased mortality, morbidity, and health care costs. However, the management of nausea and vomiting has improved greatly in recent years following the introduction of the 5-HT3-receptor antagonists, known as 'setrons.' In light of recent developments in antiemetic care, including the approval of the first neurokinin-1-receptor antagonist aprepitant (Emend; Merck and Company, Inc...
2004: Oncologist
https://www.readbyqxmd.com/read/15378559/pharmacokinetics-metabolism-and-excretion-of-intravenous-l4c-palonosetron-in-healthy-human-volunteers
#14
Randall Stoltz, Simona Parisi, Ajit Shah, Alberto Macciocchi
Palonosetron (Aloxi(R), Onicit(R)) is a potent, single stereoisomeric 5-HT(3) receptor antagonist developed to prevent chemotherapy-induced nausea and vomiting. The pharmacokinetics and metabolic disposition of a single intravenous [(14)C]-palonosetron (10 microg/kg, 0.8 microCi/kg) bolus dose were evaluated in six healthy volunteers (three males, three females) using serial blood, plasma, urine and fecal samples obtained over 10 days. The safety, tolerability and cardiac effects were assessed. Radiolabeled metabolic characterization revealed that unchanged palonosetron accounted for 71...
November 2004: Biopharmaceutics & Drug Disposition
https://www.readbyqxmd.com/read/15102873/pharmacokinetic-and-safety-evaluation-of-palonosetron-a-5-hydroxytryptamine-3-receptor-antagonist-in-u-s-and-japanese-healthy-subjects
#15
RANDOMIZED CONTROLLED TRIAL
Randall Stoltz, Jong-Chol Cyong, Ajit Shah, Simona Parisi
Palonosetron (Aloxi, Onicit) is a selective 5-HT(3) receptor antagonist recently approved by the Food and Drug Administration for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. This study was performed to determine the pharmacokinetics and assess the safety and tolerability of intravenous (IV) palonosetron in healthy U.S. and Japanese subjects. Subjects were administered a single IV dose of palonosetron, ranging from 0.3 to 90 microg/kg in either of two randomized, double-blind, placebo-controlled, ascending-dose studies (n = 80 and n = 32, respectively)...
May 2004: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/15057189/palonosetron-aloxi-for-prevention-of-nausea-and-vomiting-due-to-cancer-chemotherapy
#16
(no author information available yet)
No abstract text is available yet for this article.
March 29, 2004: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/14640928/palonosetron-a-unique-5-ht3-receptor-antagonist-for-the-prevention-of-chemotherapy-induced-emesis
#17
REVIEW
Steven M Grunberg, James M Koeller
Palonosetron (Aloxi) is a 5-HT(3)-receptor antagonist antiemetic indicated for the prevention of acute and delayed nausea and vomiting following moderately emetogenic chemotherapy and for acute nausea and vomiting following highly emetogenic chemotherapy. Although it is the fourth member of this class to enter the US market, palonosetron is distinguished by distinct pharmacological characteristics. It has a higher binding affinity for the 5-HT(3 )receptor and a terminal serum half-life at least four times greater than any other available agent of this class (approximately 40 h)...
December 2003: Expert Opinion on Pharmacotherapy
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"